This Month's Profile Group: Nanomedicine: Will It Get Big?, features profiles of Blend Therapeutics, Kala Pharmaceuticals, Qualiber, and Uroboros Technologies. Plus these Start-Ups Across Health Care: Ceterix Orthopaedics, Flux Medical, Neuros Medical, and Tunitas Therapeutics.
Big drugmakers will be watching closely to see if second-generation nanoparticlue companies can program small particles to pack big pharmaceutical effects.
Prolific entrepreneurs Robert Langer and Omid Farokhzad have formed yet another nanotechnology company. This latest, called Tarveda Therapeutics Inc.,...
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
